Compare BridgeBio Pharma Inc (BBIO) vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.27B), while State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.52. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, State Street SPDR Bloomberg 1-3 Month T-Bill ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | BIL | |
|---|---|---|
Market Cap | $16.27B | — |
Sector | Health | Fixed Income |
52-Week High | $90.17 | $91.77 |
52-Week Low | $44.81 | $91.27 |
Enterprise Value | $17.82B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →
